Will inter partes review speed US generic drug entry?

被引：0
|
作者：
Jonathan J Darrow
Reed F Beall
Aaron S Kesselheim
机构：
[1] Jonathan J. Darrow,Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine
[2] Reed F. Beall and Aaron S. Kesselheim are at the Program On Regulation,undefined
[3] Therapeutics,undefined
[4] And Law (PORTAL),undefined
[5] Brigham and Women's Hospital and Harvard Medical School,undefined
[6] Boston,undefined
[7] Massachusetts,undefined
[8] USA.,undefined
来源：
Nature Biotechnology | 2017年 / 35卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
A new extra-judicial pathway for challenging pharmaceutical patents has intensified patent challenges and helped to clear the way for earlier generic entry.
引用
收藏
页码：1139 / 1141
页数：2
相关论文
共 50 条
  • [21] What you need to know about Inter Partes Review proceedings
    Poplin, Justin
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
  • [22] PREJUDICIAL OR PROBATIVE: DETERMINING THE ADMISSIBILITY OF DECISIONS IN INTER PARTES REVIEW PROCEEDINGS
    Sawyer, Audra
    [J]. BOSTON UNIVERSITY LAW REVIEW, 2018, 98 (01) : 263 - 301
  • [23] Interactions between Inter Partes Review and Hatch-Waxman Litigations
    Chen, Feng-Chi
    Lee, Pin-Shen
    Huang, Yun-Yu
    Wu, Huang-Chi
    Lin, Hsuan-Yu
    [J]. 2019 16TH IEEE INTERNATIONAL CONFERENCE ON COMPUTATIONAL INTELLIGENCE IN BIOINFORMATICS AND COMPUTATIONAL BIOLOGY - CIBCB 2019, 2019, : 352 - 355
  • [24] Generic Entry, Reformulations and Promotion of SSRIs in the US
    Haiden A. Huskamp
    Julie M. Donohue
    Catherine Koss
    Ernst R. Berndt
    Richard G. Frank
    [J]. PharmacoEconomics, 2008, 26 : 603 - 616
  • [25] Generic entry, reformulations and promotion of SSRIs in the US
    Huskamp, Haiden A.
    Donohue, Julie M.
    Koss, Catherine
    Berndt, Ernst R.
    Frank, Richard G.
    [J]. PHARMACOECONOMICS, 2008, 26 (07) : 603 - 616
  • [26] Barriers to entry, brand advertising, and generic entry in the US pharmaceutical industry
    Morton, FMS
    [J]. INTERNATIONAL JOURNAL OF INDUSTRIAL ORGANIZATION, 2000, 18 (07) : 1085 - 1104
  • [27] Association between US Pharmacopeia (USP) monograph standards, generic entry and prescription drug costs
    Murimi-Worstell, Irene B.
    Ballreich, Jeromie M.
    Seamans, Marissa J.
    Alexander, G. Caleb
    [J]. PLOS ONE, 2019, 14 (11):
  • [28] ENTRY THREATS AND PRICING IN THE GENERIC DRUG INDUSTRY
    Tenn, Steven
    Wendling, Brett W.
    [J]. REVIEW OF ECONOMICS AND STATISTICS, 2014, 96 (02) : 214 - 228
  • [29] THE EFFECT OF ARBITRATION AGREEMENTS ON THE AMERICA INVENTS ACT'S INTER PARTES REVIEW PROCEDURE
    Budiardjo, Luke Ali
    [J]. COLUMBIA LAW REVIEW, 2018, 118 (01) : 83 - 126
  • [30] Generic drug approval: A US perspective
    Nagori, B. P.
    Mathur, V.
    Garg, S.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (03) : 541 - 545
12345